Pefloxacin mesylate is well absorbed by the oral route. The antimicrobial activity in dog, cynomolgus monkey, and human plasma was essentially due to unchanged drug which respectively accounted for 64, 94, and 84% of the total activity (ratios derived from relative area under the curve [AUC] values). Half-lives ranged from 1.9 h in mice to 8.6 h in humans. Protein binding was weak, about 20% in plasma. Except in brain, concentrations in most of the organs and tissues tested in rats and dogs were higher than the plasma levels. Microbiological activity in urine was mainly due to pefloxacin and norfloxacin, the N-desmethyl metabolite. The norfloxacin/pefloxacin ratios were 0 in mice, ca. 1 in rats and dogs, 1.6 in cynomolgus monkeys, and 2.3 in humans. The principal urinary compounds were unchanged drug in mice, pefloxacin glucuronide and pefloxacin N-oxide in rats and dogs, norfloxacin and pefloxacin in monkeys, and pefloxacin N-oxide and norfloxacin in humans. The urinary recovery of identified metabolites was 29.5% of the dose in mice, 37.8% in rats, 36.3% in dogs, 26.5% in monkeys, and 58.9% in humans. Biliary excretion occurred and was extensive in rats and dogs, mainly as a glucuronide conjugate of the drug. In rat and human bile, the main active compound was unchanged pefloxacin.
Pefloxacin [1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-quinoline-3-carboxylic acid (1589 RB)] has a high order of in vitro activity against gram-positive and gram-negative bacteria (2, 6, 7) and when administered as a single dose has significant activity against infections with Staphylococcus aureus, Pseudomonas aeruginosa, and Serratia marcescens in mice (unpublished data). This paper concerns the absorption, distribution, metabolism, and elimination of pefloxacin dihydrate mesylate in mice, rats, dogs, cynomolgus monkeys, and humans.
(These results were presented in part at the 13th International Congress of Chemotherapy, Vienna, Austria, 1983.)
MATERIALS AND METHODS
Drug and reagents. Pefloxacin dihydrate mesylate ( Fig. 1 ) and possible metabolites were synthesized in our laboratories; the structures are shown in Fig. 2 . All reagents were of analytical grade. Doses and concentrations are expressed with reference to the anhydrous substance except for doses administered to rats and dogs, which are expressed in terms of the dihydrate (the degree of hydration of the salt was unknown when the early experiments were performed); hence, the quoted doses of 10, 25, and 50 mg/kg in these animals correspond to 9.2, 23.1, and 46.2 mg of anhydrous pefloxacin per kg.
In vivo experiments. Male Swiss mice (24 to 28 g), male Wistar rats (200 to 300 g), male and female beagle dogs (13 to 16 kg), and male Macacafascicularis monkeys (3.2 to 4.4 kg) were treated after a 17-h fast. All animal experiments were carried out in our laboratory except for the monkey assays, which were performed at IFM Center (Evreux, France). Pefloxacin mesylate was dissolved in saline for intravenous administration. Oral or intraduodenal doses were given to mice, rats, and monkeys as aqueous solutions and to the dogs as capsules. Healthy human male volunteers (54 to 75 kg, 19 to 29 years old) were given 400 or 800 mg as capsules or tablets. Blood samples collected on heparin were obtained * Corresponding author. from rodents by orbicular puncture, and those from the other species were obtained by venipuncture. Plasma was separated by centrifugation. For the tissue distribution experiments in rats and dogs, organs were excised, weighed, placed in 10 to 20 times their weight of 0.1 M monobasic potassium phosphate buffer (pH 8), heated at 80°C in a water bath for 15 min, and homogenized (Polytron Kinematica, Lucerne, Switzerland). Urine was collected from 0 to 24 and 24 to 48 h after administration of the drug; an additional collection of 48-to 72-h urine was made in monkeys and humans. Biliary excretion was studied in rats anesthetized with ethyl carbamate (1 g/kg intraperitoneally). Bile was collected from a polyethylene catheter introduced by surgical procedure into the common bile duct. Collections made over the periods indicated after drug administration were pooled. Biliary excretion was also studied in one dog anesthetized with chloralose-ethyl carbamate (0.06 to 0.75 g/kg, intravenously). After ligature of the cystic duct, a polyethylene catheter was introduced into the common bile duct. Biliary excretion was studied in human patients with T-tubes in the common duct. Bile samples were collected 1, 2, 4, 8, 12, and 24 h after administration of the drug.
Pefloxacin assays. (i) Microbiological assay. The cup-diffusion method (1) was used with Bacillus subtilis ATCC 6633 as the reference bacterium and pH 8 medium. The assay was sensitive to 0.06 pRg of pefloxacin per ml.
(ii) Fluorimetric assay. A sample of plasma, bile, or tissue homogenate at pH 7.4 (0.5 M phosphate buffer) was extracted with 10 ml of chloroform. The chloroform phase was separated and then reextracted with 4 ml of 1 N acetic acid. This extract containing pefloxacin was subjected to fluorimetry with a Jobin Yvon JY 3-D spectrofluorimeter (X excitation = 331 nm, X emission = 441 nm, uncorrected values). Calibration curves were prepared over the range 0.5 to 4 ,ug. Recovery was 85% and precision was 2 to 4%. This assay was used for the determination of drug tissue and plasma levels in rats and dogs and for biliary levels in rats. Comparison of the fluorimetric assay and a specific high-pressure liquid chromatography (HPLC) assay of pefloxacin (3) made on samples of dog plasma (Fig. 3 ) and rat bile (see Table 7 ). Agreement between both methods was good; the specificity for tissue assays was not tested. The sensitivity was 0.1 ,ug of pefloxacin per ml of plasma or bile and 0.1 ,ug per g of tissue.
(iii) HPLC. Pefloxacin and metabolites were separated by ion-pair chromatography by using tetrabutylammonium iodide and a C18 silica column (Lichrosorb RP18; E. Merck 7,. AG, Darmstadt, Germany). The effluent was monitored at 270 nm. This assay has been described elsewhere (3) Table 2 for dosages.
H2SO4, or by bioautography with Escherichia coli 01SISM as the reference strain and triphenyltetrazolium chloride as the stain. In all systems containing ammonia, pefloxacin glucuronide was converted to an unidentified compound of higher Rf value (presumably pefloxacin amide). Samples were also examined by TLC on silica plates after hydrolysis with ,B-glucuronidase with a n-butanol-acetic acid-water (2:1:1) or methanol-water (8:1) mixture (vol/vol) as the mobile phase and naphthoresorcinol-sulfuric acid spray as the detection reagent.
Quantitative determination of metabolites. Pefloxacin, norfloxacin, oxonorfloxacin, and oxopefloxacin were assayed in urine by the HPLC method described previously. Total pefloxacin in urine and bile was assayed by the same method after hydrolysis of the glucuronide conjugate (heating at 80°C for 1 h in 2.5 N NaOH). This method was faster than enzymatic hydrolysis and did not convert N-oxide pefloxacin to parent compound. The concentration of conjugate was taken to be the difference between the total and free pefloxacin levels. The N-oxide metabolite in urine was assayed by TLC. Samples of 2 ml of urine (pH 6 to 7) were passed through 2 g of Amberlite XAD2 resin. The column was washed with 20 ml of distilled water and eluted with 10 ml of ethanol-water (80:20 [vol/vol]). The solvent was evaporated and the residue was moistened with 0.5 ml of the above mixture to which ammonia was added to 5% (vol/vol 8.8 and 56 jig * h/ml. In dogs given a 50-mg/kg dose of drug orally, the peak pefloxacin level was 14.9 ,ug/ml as measured by fluorimetry, 17 ,ug/ml as measured by HPLC, and 27.5 ,ug/ml as measured by bioassay. The ratio between the AUC values from HPLC (100.6 ,ug * h/ml) and bioassay (156. 4 ,ug* h/ml) was 0.64 0.01 (mean ± standard error). In monkeys and humans, activity in plasma was due largely to unchanged drug. The peak levels were 12.4 p.g/ml (HPLC assay) and 13.8 ,ug/ml (bioassay) in monkeys given 25 mg/kg and 3.84 and 3.77 ,ug/ml, respectively, in humans given 0. Table 3 . After a single dose of 100 mg/kg, tissue levels in rats were two to three times greater than in plasma except for in the brain, in which concentrations were onefifth or less than plasma levels, and in the liver, kidney, and spleen, where concentrations were three to six times greater. The tissue/plasma ratios were similar after 15 repeated doses. In dogs, after daily dosing with 100 mg/kg for 6 weeks, tissue levels were generally three to five times greater than the plasma level except in the cerebrospinal fluid and brain, where they were two to three times less, and in the liver, where they were 8 to 10 times greater. The high concentration of conjugated drug in bile reflects the important part played by the liver in the metabolism of pefloxacin.
Metabolism. (i) Principal metabolites in rat, dog, monkey, and human plasma. The major metabolites in rat and dog plasma were pefloxacin glucuronide, pefloxacin N-oxide, and norfloxacin. The last two were also found in monkey and human plasma, but no conjugate was detected. Figure 4 shows a typical chromatogram obtained from 0-to 8-h pooled plasma in these species.
(ii) Principal metabolites in urine and bile. Urine and bile of mice contained unchanged drug and two identified metabolites, the glucuronide and N-oxide. Urine also contained three unidentified metabolites. In rat and dog urine and bile, the principal metabolites were the glucuronide, the N-oxide, and norfloxacin. Substantial amounts of unchanged drug were also present. Typical HPLC chromatograms of an XAD2 extract of rat urine and of dog bile are shown in Fig. 5 Fig. 5 . Biliary excretion in monkeys and humans was less extensive than in rats and dogs. The most common metabolites were the parent compound, pefloxacin glucuronide, pefloxacin N-oxide, and norfloxacin.
(iii) Antibacterial activity of the metabolites. The activities of pefloxacin and the identified metabolites were determined (see Table 4 ). Norfloxacin was found to be as active in vitro as pefloxacin. The N-oxide and glucuronide analogs of pefloxacin showed little activity.
Urinary excretion of pefloxacin and principal metabolites. Urinary HPLC data on pefloxacin and norfloxacin concentrations and the results of the microbiological assay in urine are shown in Table 5 . Except in mice, which do not produce the metabolite and have the highest recovery of unchanged drug (16.4%), the antimicrobial activity in urine was essentially due to pefloxacin and norfloxacin. Recoveries of both compounds were similar in rats and dogs (6.9 and 5.9%, respectively, in rats and 4.7% for both compounds in dogs). Norfloxacin predominated in monkeys and humans, the values being 9.3% norfloxacin and 5.9o pefloxacin in the former and 20.2% norfloxacin and 8.7% pefloxacin in the latter. In humans, the two compounds accounted for 29% of the administered dose, this being the highest recovery in any subject. Urinary recovery of pefloxacin and its principal metabolites are shown in Table 6 . Total recovery of parent drug and identified metabolites was the highest in humans (about 59%o of the dose). a The dosages used were: rat (n = 3), 50 mg/kg; mouse (n = 5), 50 mg/kg; dog (n = 4), 50 mg/kg; monkey (n = 3), 25 mg/kg; human (n = 6), 0.4 g per person.
ANTIMICROB. AGENTS CHEMOTHER. Table 1 ). Fluorescence observation ( ) and bioautography (....) borders are shown. References: I, pefloxacin; II, norfloxacin; III, pefloxacine N-oxide.
Biliary excretion of pefloxacin. The microbiological activity and pefloxacin content of bile were determined before and after alkaline hydrolysis in rats given 10 mg of drug per kg by the intravenous or intraduodenal route ( Table 7) . Most of the antimicrobial activity detected was due to pefloxacin. The similar concentrations obtained by bioassay and fluorimetric assay after hydrolysis (intraduodenal dosing) suggested that glucuronide conjugate of pefloxacin might be slightly active, since free activity determined by bioassay was higher than free pefloxacin levels. The concentration of pefloxacin glucuronide was five to eight times greater than that of free drug. Absorption of pefloxacin mesylate was extensive since biliary elimination over 0 to 8 h was similar with both dose routes (Fig. 6) . The values for free and total (free plus conjugated) pefloxacin were, respectively, 3.94 + 0.18% and 34.54 ± 2.52% after intravenous dosing and 5.43 ± 0.85% and 34.58 ± 5.79% after intraduodenal dosing. Bile was also an important route of elimination in dogs. In one animal given 5 mg/kg intravenously, levels of free pefloxacin reached 102 to 259 ,ug/ml (HPLC assay) or 117 to 344 ,ug/ml (microbiological data) from 0.5 to 10 h after dosing. Total recovery of free drug during the first 12 h accounted for 5.3% of the administered dose and recovery of the glucuronide accounted for 15.1% (Fig. 6) . Figure 6 shows the microbio- logical activity and pefloxacin levels found in humans after a 0.8-g dose. Microbiologically active levels between 5 and 30 ,ug/ml were found between 2 and 24 h after dosing, the activity mainly being due to the parent compound (AUC RAT (4) , whereas those of pefloxacin after a twofold dose are 31.8, 71.7, 78.7, and 127 ,ug/ml or g. After repeated dosages in dogs, the concentrations of pefloxacin in heart, lung, liver, kidney, spleen, and muscle are from 2.7 to 9.4 times the plasma levels, whereas those of enoxacin are from 1.5 to S times the plasma levels. Pefloxacin is excreted in urine and bile mainly as metabolites, except in mice where the parent compound predominates. In urine, the N-desmethyl metabolite (norfloxacin) and unchanged drug are the main compounds responsible for the activity encountered in all species tested except mouse. The antibacterial activity in urine of mice, rats, and dogs to which pefloxacin mesylate was given orally represented recoveries of 20.4, 12, and 8.7% of the dose, values which are 1.6 to 4.6 times higher than those obtained with norfloxacin and 3.4 to 7.4 times lower than those reached with enoxacin (4) . Total 
